Development/NN
of/IN
a/DT
Knowledge/NN
Base/NN
for/IN
Korean/JJ
./.
====================
Pharmacogenomics/NNS
Research/NN
Network/NN
====================
Pharmacogenomics/NNS
research/NN
requires/VBZ
an/DT
intelligent/JJ
in­/IN
tegration/NN
of/IN
large-scale/JJ
genomic/JJ
and/CC
clinical/JJ
data/NNS
with/IN
====================
public/JJ
and/CC
private/JJ
knowledge/NN
resources/VBZ
./.
====================
We/PRP
developed/VBD
a/DT
web-based/JJ
knowledge/NN
base/NN
for/IN
KPRN/NN
(/(
Korea/NN
Pharmacogenomics/NNS
Research/NN
Network/NN
,/,
http/NN
:/:
//kprn.snubi/LS
./.
====================
org//RB
)/)
./.
====================
Four/CD
major/JJ
types/NNS
of/IN
information/NN
is/VBZ
integrated/VBN
;/:
ge­/RB
netic/JJ
variation/NN
,/,
drug/NN
information/NN
,/,
disease/NN
information/NN
,/,
and/CC
literature/NN
annotation/NN
./.
====================
Eighteen/CD
Korean/JJ
pharmacoge­/NN
nomics/NNS
research/NN
groups/NNS
in/IN
collaboration/NN
have/VBP
submitted/VBN
859/CD
genotype/NN
data/NNS
sets/NNS
for/IN
91/CD
disease-related/JJ
genes/NNS
./.
====================
Integrative/JJ
analysis/NN
and/CC
visualization/NN
of/IN
the/DT
large/JJ
collec­/JJ
tion/NN
of/IN
data/NNS
supported/VBD
by/IN
integrated/JJ
biomedical/JJ
path­/NN
ways/NNS
and/CC
ontology/NN
resources/VBZ
are/VBP
provided/VBN
with/IN
a/DT
user-friendly/RB
interface/NN
and/CC
visualization/NN
engine/NN
empowered/VBN
by/IN
Generic/JJ
Genome/NN
Browser/NN
./.
====================
Human/JJ
Genome/NN
map/VBP
is/VBZ
nearly/RB
completed/VBN
./.
====================
Pharmacoge­/NN
netics/NNS
and/CC
Pharmacogenomics/NNS
which/WDT
deal/JJ
with/IN
the/DT
ge­/JJ
netic/JJ
or/CC
genomic/JJ
basis/NN
underlying/VBG
variable/JJ
drug/NN
re­/NN
sponses/NNS
in/IN
individuals/NNS
have/VBP
become/VBN
the/DT
center/NN
of/IN
inter­/JJ
est/JJS
all/DT
over/IN
the/DT
world/NN
./.
====================
In/IN
this/DT
situation/NN
,/,
it/PRP
is/VBZ
recognized/VBN
that/DT
pharmacogenomic/JJ
and/CC
pharmacogenetic/JJ
studies/NNS
form/VBP
a/DT
field/NN
of/IN
study/NN
that/IN
can/MD
be/VB
applied/VBN
in/IN
clinical/JJ
medi­/JJ
cine/NN
at/IN
the/DT
earliest/JJS
time/NN
./.
====================
And/CC
many/JJ
biomedicalogists/NNS
are/VBP
interested/VBN
in/IN
this/DT
field/NN
because/IN
they/PRP
believe/VBP
that/IN
it/PRP
can/MD
make/VB
individualized/VBD
therapy/NN
possible/JJ
./.
====================
It/PRP
is/VBZ
expected/VBN
that/DT
a/DT
technique/NN
of/IN
individual/JJ
therapy/NN
in/IN
genetic/JJ
basis/NN
will/MD
be/VB
put/JJ
to/TO
practical/JJ
use/NN
in/IN
patient/NN
====================
treatment/NN
within/IN
10/CD
years/NNS
./.
====================
Experts/NNS
in/IN
this/DT
field/NN
have/VBP
tried/VBN
to/TO
apply/RB
the/DT
technique/NN
to/TO
a/DT
part/NN
of/IN
treatment/NN
with/IN
drugs/NNS
although/IN
there/EX
still/RB
remains/VBZ
limitation/NN
./.
====================
At/IN
present/JJ
,/,
there/EX
is/VBZ
a/DT
centralized/JJ
database/NN
,/,
Pharm/NN
GKB/NN
(/(
Klein/NN
eta/./FW
,/,
2001/CD
)/)
(/(
Pharmacogenomics/NNS
Knowledge/NN
Base/NN
)/)
,/,
where/WRB
researchers/NNS
store/RB
the/DT
outcome/NN
of/IN
the/DT
phar­/NN
macogenomics/NNS
study/NN
world/NN
wide/JJ
./.
====================
PharmGKB/NN
provides/VBZ
the/DT
functions/NNS
in/IN
which/WDT
we/PRP
can/MD
collect/VB
and/CC
search/VB
for/IN
the/DT
result/NN
of/IN
study/NN
about/IN
what/WP
drug/NN
response/NN
occurs/VBZ
in/IN
in­/FW
dividuals/NNS
according/VBG
to/TO
genetic/JJ
variation/NN
./.
====================
The/DT
standard/JJ
of/IN
data/NNS
model/NN
for/IN
pharmacogenomics/NNS
data/NNS
,/,
however/RB
,/,
is/VBZ
not/RB
present/JJ
,/,
yet/RB
./.
====================
Moreover/RB
,/,
it/PRP
is/VBZ
hard/VBN
to/TO
find/VB
a/DT
database/NN
ex­/NN
cept/NN
PharmGKB/NN
which/WDT
collects/VBZ
pharmacogenomics/NNS
data/NNS
./.
====================
As/IN
a/DT
group/NN
of/IN
large/JJ
research/NN
collaboration/NN
,/,
KPRN/NN
felt/JJ
the/DT
need/NN
of/IN
having/VBG
its/PRP$
own/JJ
repository/JJ
system/NN
with/IN
in­/JJ
tegrated/VBN
biomedical/JJ
resources/VBZ
./.
====================
The/DT
present/JJ
study/NN
intends/VBZ
to/TO
deal/JJ
with/IN
pharmacogenomics/NNS
data/NNS
repository/JJ
system/NN
being/VBG
developed/VBN
in/IN
KPRN/NN
./.
====================
Its/PRP$
goals/NNS
include/VBP
central­/NN
ization/NN
of/IN
the/DT
domestic/JJ
pharmacogenomics/NNS
data/NNS
,/,
pre­/VBP
venting/VBG
duplication/NN
of/IN
similiar/JJ
research/NN
,/,
and/CC
information­/JJ
sharing/VBG
among/IN
the/DT
joint/NN
research/NN
team/JJ
as/IN
well/RB
as/IN
with/IN
the/DT
general/JJ
research/NN
community/NN
./.
====================
It/PRP
intends/VBZ
to/TO
provide/VB
ge­/JJ
nomic/JJ
function/NN
information/NN
about/IN
sequence/NN
variance/NN
as/IN
well/RB
as/IN
expression/NN
,/,
extending/VBG
it/PRP
to/TO
be/VB
knowledge-based/VBN
./.
====================
1/CD
./.
====================
PharmGKB/NN
XML/NN
schema/NN
====================
PharmGKB/NN
is/VBZ
a/DT
Knowledge-base/NN
developed/VBD
at/IN
====================
the/DT
Stanford/NN
University/NN
for/IN
the/DT
function/NN
of/IN
searching/VBG
and/CC
retrieving/VBG
the/DT
result/NN
of/IN
research/NN
in/IN
pharmacogenomics/NNS
(/(
http/NN
:/:
//www.pharmgkb.org//JJ
)/)
./.
====================
Its/PRP$
XML/NN
schema/NN
explains/VBZ
information/NN
about/IN
sequence/NN
variation/NN
,/,
drug/NN
data/NNS
,/,
and/CC
phenotype/NN
data/NNS
./.
====================
It/PRP
describes/VBZ
the/DT
information/NN
of/IN
side/JJ
effects/NNS
from/IN
a/DT
drug/NN
treatment/NN
that/WDT
are/VBP
caused/VBN
by/IN
sequence/NN
variation/NN
./.
====================
One/CD
can/MD
find/VB
the/DT
details/NNS
of/IN
the/DT
schema/NN
at/IN
http/NN
:/:
//www.pharmgkb.org/schema/index.html//JJ
./.
====================
2/CD
./.
====================
Aperon/NN
drug/NN
database/NN
====================
We/PRP
use/VBP
the/DT
drug/NN
database/NN
made/VBD
in/IN
Aperon/NN
(/(
Kaiser/NN
,/,
2005/CD
)/)
to/TO
capture/NN
the/DT
name/NN
of/IN
drug/NN
./.
====================
Presently/RB
,/,
Aperon/NN
is/VBZ
also/RB
used/VBN
by/IN
PharmGKB/NN
./.
====================
It/PRP
catalogs/NNS
3,885/CD
drug/NN
names/NNS
,/,
9,176/CD
generic/JJ
names/NNS
,/,
and/CC
9,177/CD
trade/VBP
name/NN
./.
====================
3/CD
./.
====================
Medical/JJ
Subjects/NNS
Heading/JJ
(/(
MeSH/NN
)/)
====================
MeSHMeSH/NN
(/(
Schulman/NNP
etal./FW
,/,
2000/CD
)/)
,/,
a/DT
thesaurus/NN
made/VBD
by/IN
NLM/NN
(/(
National/JJ
Library/JJ
of/IN
Medicine/NN
)/)
,/,
is/VBZ
used/VBN
for/IN
indexing/VBG
an/DT
article/NN
in/IN
MEDLINE/NN
./.
====================
It/PRP
provides/VBZ
a/DT
consistent/JJ
way/NN
for/IN
searching/VBG
the/DT
information/NN
that/IN
includes/VBZ
different/JJ
terms/NNS
for/IN
the/DT
same/JJ
concepts/NNS
./.
====================
For/IN
instance/NN
,/,
a/DT
malignant/JJ
tumor/NN
can/MD
be/VB
ordinarily/RB
named/VBN
either/CC
'neoplasm/NN
'/``
or/CC
'cancer*/JJ
./.
====================
In/IN
MeSH/NN
,/,
however/RB
,/,
neoplasm/NN
is/VBZ
adopted/VBN
./.
====================
Also/RB
,/,
MeSH/NN
====================
terms/NNS
old/JJ
people/NN
'aged/JJ
'/``
./.
====================
4/CD
./.
====================
USCS/NNS
GoldenPat/NN
====================
Our/PRP$
knowledge/NN
base/NN
uses/VBZ
the/DT
GoldenPath/NN
(/(
Kent/JJ
et/FW
al./FW
,/,
2005/CD
;/:
Karolchik/NN
etal./FW
,/,
2003/CD
)/)
developed/VBD
at/IN
the/DT
University/JJ
of/IN
California/NN
to/TO
capture/NN
the/DT
position/NN
where/WRB
a/DT
sequence/NN
variation/NN
occurred/VBD
./.
====================
GoldenPath/NN
enables/VBZ
the/DT
use/NN
of/IN
absolute/JJ
coordinate/JJ
system/NN
for/IN
a/DT
position/NN
of/IN
variation/NN
on/IN
Human/JJ
Chromosome/NN
Map/NN
,/,
allowing/VBG
a/DT
consistent/JJ
positioning/JJ
of/IN
variations/NNS
and/CC
annotation/NN
on/IN
the/DT
basis/NN
of/IN
the/DT
position/NN
of/IN
variation/NN
./.
====================
ChromosomeNumber/NN
:/:
BasePosition/NN
====================
For/IN
example/NN
,/,
'chr2:23451703/CD
'/``
indicates/VBZ
the/DT
23451703/CD
rd/JJ
position/NN
on/IN
the/DT
2nd/JJ
chromosome/NN
./.
====================
5/CD
./.
====================
Genew/JJ
(/(
Human/JJ
Gene/NN
Nomenclature/NN
Database/NN
)/)
====================
We/PRP
use/VBP
the/DT
gene/NN
name/NN
provided/VBD
by/IN
Genew/JJ
(/(
Wain/NN
et/FW
al./FW
,/,
====================
2002/CD
)/)
to/TO
associate/VB
it/PRP
with/IN
the/DT
information/NN
of/IN
a/DT
sequence/NN
variation/NN
./.
====================
Genew/JJ
is/VBZ
the/DT
precisely/RB
verified/VBN
database/NN
by/IN
editors/NNS
in/IN
HGNC/NN
(/(
Human/JJ
Gene/NN
Nomenclature/NN
Committee/NN
)/)
for/IN
denominating/VBG
name/NN
and/CC
symbol/NN
of/IN
human/JJ
gene/NN
./.
====================
This/DT
database/NN
includes/VBZ
gene/NN
name/NN
,/,
gene/NN
symbol/NN
,/,
and/CC
alias/NNS
symbol/NN
./.
====================
6/CD
./.
====================
Generic/JJ
Genome/NN
Browser/NN
(/(
GGB/NN
)/)
====================
We/PRP
use/VBP
GGB/NN
(/(
Stein/NN
etal./FW
,/,
2002/CD
)/)
(/(
Generic/JJ
Genome/NN
Browser/NN
)/)
to/TO
display/VB
information/NN
of/IN
both/DT
sequence/NN
variance/NN
and/CC
Human/JJ
genome/NN
which/WDT
are/VBP
collected/VBN
./.
====================
It/PRP
is/VBZ
possible/JJ
for/IN
GGB/NN
to/TO
show/VB
sequence-based/VBN
information/NN
such/JJ
as/IN
genome/NN
contig/NN
,/,
genome/NN
information/NN
,/,
STS/NN
(/(
Sequence/NN
Tag/NN
Site/NN
)/)
,/,
SNP/NN
(/(
Single/JJ
Nucleotide/JJ
Polymorphism/NN
)/)
,/,
so/RB
on/IN
and/CC
so/RB
forth/IN
by/IN
track/NN
./.
====================
And/CC
also/RB
the/DT
GGB/NN
is/VBZ
designed/VBN
to/TO
be/VB
able/JJ
to/TO
be/VB
linked/VBN
with/IN
other/JJ
databases/NNS
as/IN
each/DT
of/IN
track/NN
information/NN
./.
====================
We/PRP
adopted/VBD
this/DT
browser/NN
to/TO
indicate/VB
the/DT
information/NN
of/IN
allele/NN
frequency/NN
entered/VBD
by/IN
users/NNS
./.
====================
To/TO
store/VB
and/CC
search/VB
pharmacogenomics/NNS
data/NNS
,/,
we/PRP
de­/VBP
fined/JJ
and/CC
modeled/JJ
the/DT
relationship/NN
between/IN
sequence/NN
variance/NN
information/NN
,/,
drug/NN
information/NN
,/,
and/CC
phenotype/NN
information/NN
that/IN
describe/VBP
pharmacokinetic/JJ
or/CC
pharmaco-/NN
====================
dynamic/JJ
effect/NN
which/WDT
is/VBZ
different/JJ
in/IN
sequence/NN
variance/NN
for/IN
dosage/JJ
./.
====================
For/IN
the/DT
standardization/NN
of/IN
entering/VBG
information/NN
for/IN
sequence/NN
variance/NN
,/,
we/PRP
use/VBP
the/DT
Gene/NN
Symbol/NN
provided/VBD
by/IN
Genew/JJ
./.
====================
We/PRP
accept/VBP
MeSH/NN
terms/NNS
as/IN
the/DT
standard/JJ
for/IN
disease/NN
names/NNS
in/IN
phenotype/NN
data/NNS
./.
====================
The/DT
drug/NN
names/NNS
are/VBP
taken/VBN
from/IN
Aperon/NN
database/NN
./.
====================
The/DT
relationship/NN
of/IN
each/DT
of/IN
information/NN
is/VBZ
illustrated/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
In/IN
order/NN
to/TO
add/VB
literature/NN
annotation/NN
information/NN
,/,
we/PRP
have/VBP
developed/VBN
a/DT
system/NN
for/IN
inputting/VBG
highly/RB
curated/VBN
annotation/NN
of/IN
each/DT
gene/NN
,/,
drug/NN
,/,
and/CC
phenotype/NN
from/IN
documents/NNS
published/VBN
already/RB
./.
====================
Fig/NN
./.
====================
2/CD
shows/VBZ
such/JJ
a/DT
form/NN
through/IN
which/WDT
users/VBZ
can/MD
input/VB
data/NNS
in­/VBP
to/TO
the/DT
system/NN
./.
====================
We/PRP
accomplish/VBP
the/DT
visualization/NN
of/IN
in­/JJ
formation/NN
of/IN
sequence/NN
variance/NN
by/IN
integrating/VBG
the/DT
func­/JJ
tionalities/NNS
supported/VBD
by/IN
the/DT
Generic/JJ
Genome/NN
Browser/NN
./.
====================
1/CD
)/)
Information/NN
of/IN
Sequence/NN
variance/NN
====================
This/DT
part/NN
describes/VBZ
information/NN
of/IN
experiment/JJ
about/RB
se­/RB
====================
quence/RB
information/NN
genotyped/VBD
(/(
i.e/FW
./.
====================
allele/NN
position/NN
,/,
al­/RB
leles/NNS
,/,
allele/NN
frequency/NN
,/,
and/CC
amino/NN
acid/NN
transition/NN
and/CC
Gene/NN
symbol/NN
)/)
./.
====================
Actually/RB
,/,
the/DT
marking/VBG
rule/JJ
in/IN
indicating/VBG
allele/NN
po­/NN
sition/NN
exists/VBZ
already/RB
./.
====================
For/IN
example/NN
,/,
``/NNP
CYP2C9/NN
,/,
Arg144Cys/NNS
''/CD
means/NNS
that/DT
amino/NN
acid/NN
transition/NN
occurs/VBZ
at/IN
the/DT
144th/JJ
po­/NN
sition/NN
of/IN
CYP2C9/NN
gene/NN
,/,
changing/VBG
Arg/NN
to/TO
Cys/NNS
./.
====================
But/CC
the/DT
re­/NN
sult/NN
may/MD
vary/VB
depending/VBG
where/WRB
the/DT
experimenter/NN
count/NN
as/IN
the/DT
1st/JJ
position/NN
of/IN
the/DT
gene/NN
./.
====================
Thus/RB
we/PRP
adopt/VBP
an/DT
abso­/JJ
lute/VBP
coordinate/VBP
system/NN
by/IN
using/VBG
GoldenPath/NN
position/NN
./.
====================
It/PRP
prevents/VBZ
ambiguity/NN
which/WDT
is/VBZ
caused/VBN
by/IN
using/VBG
relative/JJ
po­/NN
sition/NN
information/NN
and/CC
we/PRP
need/VBD
it/PRP
to/TO
combine/VB
our/PRP$
data­/NNS
base/NN
with/IN
the/DT
others/NNS
./.
====================
To/TO
mark/VB
alleles/NNS
,/,
we/PRP
adopted/VBD
the/DT
for­/JJ
mat/VBP
described/VBN
below/IN
./.
====================
The/DT
notation/NN
of/IN
amino/NN
acid/NN
transition/NN
is/VBZ
designed/VBN
to/TO
understand/VB
one/CD
or/CC
three-letter/IN
codes/VBZ
./.
====================
There/EX
are/VBP
two/CD
categories/NNS
in/IN
allele/NN
frequency/NN
,/,
control/NN
frequency/NN
and/CC
case/NN
frequency/NN
./.
====================
The/DT
former/JJ
corresponds/VBZ
to/TO
searching/VBG
for/IN
frequency/NN
in/IN
healthy/JJ
volunteers/NNS
,/,
the/DT
latter/JJ
in/IN
patients/NNS
./.
====================
We/PRP
used/VBD
the/DT
Genew/JJ
system/NN
to/TO
check/VB
what/WP
gene/NN
the/DT
====================
information/NN
of/IN
a/DT
sequence/NN
variation/NN
be/VB
included/VBN
by/IN
./.
====================
For/IN
a/DT
gene/NN
,/,
more/RBR
than/IN
one/CD
symbols/NNS
may/MD
exist/VB
./.
====================
In/IN
case/NN
of/IN
an/DT
alpha-1/NN
-B/NN
glycoprotein/NN
,/,
alias/RB
symbols/NNS
are/VBP
A1B/NN
,/,
ABG/NN
,/,
GAB/NN
,/,
HTSY2477/NN
and/CC
so/RB
on/IN
./.
====================
So/RB
,/,
we/PRP
need/VBD
an/DT
official/JJ
gene/NN
symbol/NN
that/DT
represents/VBZ
them/PRP
for/IN
preventing/VBG
ambiguity/NN
caused/VBD
by/IN
redundancy/NN
./.
====================
We/PRP
use/VBP
23,449/CD
official/JJ
symbols/NNS
now/RB
./.
====================
2/CD
)/)
Drug/NN
information/NN
====================
We/PRP
use/VBP
the/DT
drug/NN
database/NN
made/VBD
in/IN
Aperon/NN
to/TO
input/VB
the/DT
name/NN
of/IN
drug/NN
./.
====================
Presently/RB
,/,
it/PRP
is/VBZ
also/RB
used/VBN
by/IN
PharmGKB/NN
./.
====================
The/DT
Aperon/NN
drug/NN
database/NN
consists/VBZ
of/IN
3,885/CD
drug/NN
names/NNS
,/,
9,176/CD
generic/JJ
names/NNS
,/,
and/CC
9,177/CD
trade/VBP
names/NNS
./.
====================
When/WRB
users/NNS
search/VBP
or/CC
retrieve/JJ
drug/NN
name/NN
,/,
generic/JJ
name/NN
,/,
and/CC
trade/VBP
name/NN
simultaneously/RB
,/,
it/PRP
gives/VBZ
proper/JJ
drug/NN
name/NN
to/TO
users/NNS
to/TO
use/VB
./.
====================
3/CD
)/)
Phenotype/NN
information/NN
====================
The/DT
phenotype/NN
that/IN
the/DT
gene/NN
in/IN
point/NN
shows/VBZ
when/WRB
a/DT
drug/NN
is/VBZ
administered/VBN
into/IN
normal/JJ
group/patient/JJ
group/NN
is/VBZ
described/VBN
in/IN
phenotype/NN
information/NN
./.
====================
We/PRP
use/VBP
the/DT
MeSH/NN
====================
term/NN
to/TO
describe/VB
disease/NN
name/NN
used/VBN
for/IN
input/NN
and/CC
classify/VB
phenotype/NN
into/IN
five/CD
categories/NNS
used/VBN
in/IN
PharmGKB/NN
./.
====================
This/DT
system/NN
uses/VBZ
EAV/NN
(/(
Entity-Attribute-Value/NN
)/)
model/NN
(/(
Anjoy/NNP
eta/./FW
,/,
2003/CD
)/)
because/IN
each/DT
phenotype/NN
information/NN
is/VBZ
input/RB
in/IN
each/DT
category/NN
but/CC
can/MD
not/RB
be/VB
input/NN
as/IN
unified/JJ
or/CC
abbreviated/JJ
form/VBP
./.
====================
4/CD
)/)
Literature/JJ
Annotation/NN
====================
We/PRP
developed/VBD
a/DT
Literature/JJ
Annotation/NN
system/NN
to/TO
search/VB
for/IN
the/DT
information/NN
of/IN
pharmacogenomics/NNS
that/DT
is/VBZ
published/VBN
already/RB
because/IN
we/PRP
intend/VBP
to/TO
get/VB
literature/NN
information/NN
which/WDT
is/VBZ
highly/RB
curated/VBN
by/IN
researchers/NNS
./.
====================
The/DT
Literature/JJ
Annotation/NN
consists/VBZ
of/IN
PubMed/JJ
information/NN
,/,
keyword/JJ
,/,
abstract/JJ
,/,
related/JJ
gene/NN
,/,
drug/NN
,/,
and/CC
disease/NN
information/NN
that/IN
can/MD
be/VB
input/NN
and/CC
retrieved/VBD
./.
====================
5/CD
)/)
Visualization/NN
using/VBG
Generic/JJ
Genome/NN
Browser/NN
====================
We/PRP
used/VBD
Generic/JJ
Genome/NN
Browser/NN
(/(
GGB/NN
)/)
to/TO
visualize/VB
====================
information/NN
of/IN
sequence/NN
variance/NN
./.
====================
It/PRP
is/VBZ
possible/JJ
for/IN
GGB/NN
to/TO
show/VB
sequence-based/VBN
information/NN
by/IN
tracks/NNS
./.
====================
Also/RB
it/PRP
is/VBZ
designed/VBN
to/TO
be/VB
able/JJ
to/TO
be/VB
linked/VBN
with/IN
other/JJ
databases/NNS
as/IN
each/DT
of/IN
track/NN
information/NN
./.
====================
We/PRP
modified/VBD
this/DT
browser/NN
to/TO
indicate/VB
the/DT
information/NN
of/IN
allele/NN
frequency/NN
entered/VBD
by/IN
users/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
This/DT
paper/NN
introduces/VBZ
the/DT
knowledge/NN
base/NN
for/IN
KPRN/NN
we/PRP
have/VBP
developed/VBN
for/IN
storing/VBG
and/CC
searching/VBG
for/IN
pharmaco­/NN
genomics/NNS
data/NNS
with/IN
integrated/JJ
biomedical/JJ
resources/VBZ
./.
====================
The/DT
system/NN
includes/VBZ
sequence/NN
information/NN
from/IN
phar-/NN
macogenomic/JJ
experiment/NN
,/,
drug/NN
data/NNS
,/,
phenotype/NN
data/NNS
coincided/VBD
with/IN
the/DT
drug/NN
data/NNS
,/,
literature/NN
annotation/NN
,/,
and/CC
visualization/NN
of/IN
sequence/NN
variance/NN
information/NN
./.
====================
We/PRP
used/VBD
thesaurus/DT
in/IN
MeSH/NN
,/,
Genew/JJ
and/CC
many/JJ
standard/JJ
systems/NNS
for/IN
building/VBG
the/DT
knowledge/NN
base/NN
to/TO
describe/VB
gene/NN
in­/IN
formation/NN
,/,
drug/NN
information/NN
,/,
phenotype/NN
information/NN
./.
====================
The/DT
system/NN
enables/VBZ
to/TO
link/VB
with/IN
other/JJ
public/JJ
databases/NNS
for/IN
in­/JJ
put/NN
information/NN
and/CC
helps/VBZ
understand/VB
pharmacoge­/NN
nomics/NNS
data/NNS
by/IN
means/NNS
of/IN
visualization/NN
./.
====================
At/IN
present/JJ
,/,
859/CD
genotype/NN
data/NNS
sets/NNS
are/VBP
integrated/VBN
for/IN
91/CD
genes/NNS
by/IN
the/DT
18/CD
research/NN
groups/NNS
./.
====================
The/DT
number/NN
of/IN
input/NN
data/NNS
will/MD
ex­/VB
ponentially/RB
increase/VBP
in/IN
the/DT
near/JJ
future/JJ
./.
====================
Except/IN
for/IN
the/DT
PharmGKB/NN
in/IN
Stanford/NN
,/,
there/EX
has/VBZ
been/VBN
no/DT
standard/JJ
for/IN
storing/VBG
pharmacogenomics/NNS
data/NNS
./.
====================
But/CC
we/PRP
think/VBP
that/DT
ours/VBZ
is/VBZ
a/DT
valuable/JJ
effort/NN
to/TO
create/VB
our/PRP$
own/JJ
knowledge/NN
base/NN
for/IN
understanding/VBG
and/CC
using/VBG
pharmaco­/NN
genomics/NNS
data/NNS
./.
====================
We/PRP
hope/VBP
it/PRP
will/MD
server/RB
for/IN
the/DT
develop­/NN
ment/JJ
of/IN
a/DT
standard/JJ
for/IN
collaborative/JJ
and/CC
integrative/JJ
phar­/NN
macogenomics/NNS
research/NN
./.
====================
